2023 Guidance and Q3 Earnings

Specialty Medicines: +17% with durable growth drivers Strong contributors across portfolio Benlysta +20%: growth across all major markets; updated EULAR guidelines recommend earlier use Nucala +19%: first and only biologic approved in four EOS-driven diseases; COPD data in 2H 2024 Jemperli +>100%: launched in 1L DMMR/MSI-H primary advanced or recurrent endometrial cancer Zejula +22%: launch of consumer- friendly tablet formulation; stock expected to be utilised by year end Ojjaara: line-agnostic label meets unmet need First and only treatment indicated for myelofibrosis patients with anaemia in US 25k people in US diagnosed, >40% anaemic at diagnosis Nearly all patients are estimated to develop anaemia over the course of the disease. Launch underway in market with limited existing options for patients a Survival Ojjaara (momelotinib) Impact of anaemia in primary myelofibrosis² Mild anemia N-384; median survival 4.9 years Severe anemia: -vs Moderate anemia P<0.0001 -vs Mild anemia P<0.0001 -vs No anemia P<0.0001 Moderate anemia: -vs Mild anemia P<0.0001 -vs No anemia P<0.0001 Mild anemia: -vs No anemia P=0.007 No anemia N-159; median survival 7.9 years Moderate anemia N=159; median survival 3.4 years Severe anemia N-407; median survival 2.1 years P<0.0001 15 20 25 30 35 GSK Absolute values at AER; changes at CER, unless stated otherwise 1. Excluding COVID-19 solutions 2. Nicolosi, M., Mudireddy, M., Lasho, T.L. et al. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia 32, 1254-1258 (2018). https://doi.org/10.1038/s41375-018-0028-x 17

View entire presentation